Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 8;13(16):4657.
doi: 10.3390/jcm13164657.

MASLD-Related Hepatocarcinoma: Special Features and Challenges

Carmen Yagüe-Caballero  1   2   3 , Diego Casas-Deza  1   2   3   4 , Andrea Pascual-Oliver  1 , Silvia Espina-Cadena  1   2   3   4 , Jose M Arbones-Mainar  2   3   4   5 , Vanesa Bernal-Monterde  1   2   3   4
Affiliations
Review

MASLD-Related Hepatocarcinoma: Special Features and Challenges

Carmen Yagüe-Caballero et al. J Clin Med. .

Abstract

Metabolic-associated steatohepatitis liver disease (MASLD) currently impacts a quarter of the global population, and its incidence is expected to increase in the future. As a result, hepatocellular carcinoma associated with MASLD is also on the rise. Notably, this carcinoma does not always develop alongside liver cirrhosis, often leading to a more advanced stage at diagnosis. The challenge lies in accurately identifying patients who are at a higher risk to tailor screening processes effectively. Additionally, several therapeutic approaches are being explored to prevent hepatocellular carcinoma, although there are no universally accepted guidelines yet.

Keywords: NAFLD; NASH; cirrhosis; hepatocellular carcinoma; prevention; surveillance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Etiopathogenic pathways from hepatocellular carcinoma (HCC) to MASLD.
See this image and copyright information in PMC

References

    1. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980;55:434–438. - PubMed
    1. Han S.K., Baik S.K., Kim M.Y. Non-alcoholic fatty liver disease: Definition and subtypes. Clin. Mol. Hepatol. 2023;29:S5–S16. doi: 10.3350/cmh.2022.0424. - DOI - PMC - PubMed
    1. Eslam M., Newsome P.N., Sarin S.K., Anstee Q.M., Targher G., Romero-Gomez M., Zelber-Sagi S., Wong V.W.-S., Dufour J.-F., Schattenberg J.M., et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020;73:202–209. doi: 10.1016/j.jhep.2020.03.039. - DOI - PubMed
    1. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F., Romero D., Abdelmalek M.F., Anstee Q.M., Arab J.P., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–1986. doi: 10.1097/HEP.0000000000000520. - DOI - PMC - PubMed
    1. Younossi Z.M., Paik J.M., Stepanova M., Ong J., Alqahtani S., Henry L. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease. J. Hepatol. 2024;80:694–701. doi: 10.1016/j.jhep.2024.01.014. - DOI - PubMed

LinkOut - more resources